Evaluation of signs and symptoms of ocular surface disease after intravitreal injection

Purpose: The aim of this study is to evaluate the incidence, natural course, and distribution pattern of superficial punctate keratopathy and describe the changes in signs and symptoms of dry eye after cataract surgery. Setting: The setting of this study is University Hospital Rio Hortega and Instituto Universitario de Oftalmobiología Aplicada, Valladolid, Spain. Design: This is a prospective interventional study. Materials and Methods: In total, 55 eyes of 55 different patients with no history of dry eye underwent standard phacoemulsification through a 2.75-mm-wide corneal incision. We measured tear break-up time, Schirmer test I, and tear meniscus height, and recorded the Ocular Surface Disease Index score, fluorescein staining patterns, and photo documentation of the ocular surface before and 1 day, 1 week, and 1 month postoperatively. Patients were divided into two groups (with and without superficial punctate keratopathy development, 1 day postoperatively). Results: Patients (mean age: 75.75 ± 7.27 years) showed an incidence of 76.3% of superficial punctate keratopathy at 24 h. Location predominated in the center of the cornea until a week (32.7%) and then began to prevail in the inferior quadrant (21.8%) at 1 month. All dry eye tests were significantly worse after surgery. Ocular Surface Disease Index increased from 10.98 ± 5.05 to 15.87 ± 6.57 at 24 h ( p < .001), to 12.80 ± 5.77 at 7 days ( p < .001), and to 11.09 ± 4.63 at 1 month ( p = .90). Fluorescein staining patterns got worse 24 h postoperatively with a score of 2.12 using the National Eye Institute/Industry–recommended guidelines staining grid. Average break-up time values were significantly lower at 1 day (6.61 ± 2.68),1 week (6.98 ± 2.79), and 1 month (7.05 ± 2.86) postoperatively than preoperatively (8.78 ± 2.97) ( p < .001). The mean postoperative first month Schirmer test I value (8.32 ± 3.58) was significantly lower than preoperative value (9.05 ± 3.63) ( p < .001). Conclusion: Phacoemulsification tends to induce short-term transitory ocular surface impairment manifesting as both signs and symptoms. Superficial punctate keratopathy distribution has a characteristic pattern evolution according to the postoperative time. Those patients with altered preoperative values are more likely to develop ocular surface disease and for longer time.

Download Full-text

Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication

Clinical and Experimental Ophthalmology ◽

10.1111/j.1442-9071.2012.02781.x ◽

2012 ◽

Vol 40 (7) ◽

pp. 675-681 ◽

Cited By ~ 25

Author(s):

Sudipta Ghosh ◽

Fleur O'Hare ◽

Ecosse Lamoureux ◽

Rasik B Vajpayee ◽

Jonathan G Crowston

Keyword(s):

Ocular Surface ◽

Signs And Symptoms ◽

Ocular Surface Disease ◽

Glaucoma Medication

Download Full-text

Ocular Surface Disease Signs and Symptoms of Glaucoma Patients and Their Relation to Glaucoma Medication in Finland

10.21203/rs.3.rs-845958/v1 ◽

2021 ◽

Author(s):

Minna Parkkari ◽

Petri Purola ◽

Hannu Uusitalo

Keyword(s):

Dry Eye ◽

Ocular Surface ◽

Open Angle Glaucoma ◽

Signs And Symptoms ◽

Ocular Surface Disease ◽

Pigmentary Glaucoma ◽

Eye Drops ◽

Glaucoma Medication ◽

Cross Sectional ◽

Active Compounds

Abstract Purpose: To evaluate the prevalence of ocular surface disease (OSD) signs and symptoms of glaucoma patients in relation to topical glaucoma treatment and to compare them to non-glaucomatous population. Methods: A multicenter, cross-sectional study consisting of private ophthalmology clinic visits in southern Finland. Glaucoma patients had a diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma or treated ocular hypertension. Control patients had no prior or current use of glaucoma medication. Recorded parameters included OSD signs and symptoms, used glaucoma medications during the past 6 months, and the product name and type of used antiglaucoma drugs.Results: Glaucoma patients (n = 564) showed higher severity of OSD sign parameters excluding Schirmer’s test, as well as increased dry eye sensation compared to controls (n = 51). Beta-blockers and preservative-free prostaglandins had the smallest effect on all parameters. The increasing number of active compounds and administered eye drops per day showed an association with increasing severity of OSD signs and symptoms.Conclusion: Glaucoma patients show higher prevalence of OSD signs and dry eye sensation compared to non-glaucomatous population. The use of preserved glaucoma medication, as well as high number of active compounds and eye drops increase the severity of these parameters. There are significant differences between the types of glaucoma medication used, and therefore the selection of them is important especially in patients suffering from OSD.

Download Full-text

Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments

Clinical Ophthalmology ◽

10.2147/opth.s269586 ◽

2020 ◽

Vol Volume 14 ◽

pp. 3675-3680

Author(s):

Ingeborg Stalmans ◽

Hans Lemij ◽

Jonathan Clarke ◽

Christophe Baudouin

Keyword(s):

Ocular Surface ◽

Signs And Symptoms ◽

Ocular Surface Disease ◽

Patient Dissatisfaction

Download Full-text

Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2019-315010 ◽

2019 ◽

Vol 104 (6) ◽

pp. 776-779 ◽

Cited By ~ 6

Author(s):

Yoav Nahum ◽

Michael Mimouni ◽

Eitan Livny ◽

Irit Bahar ◽

Emmilia Hodak ◽

...

Keyword(s):

Risk Factors ◽

Atopic Dermatitis ◽

Dry Eye ◽

Ocular Surface ◽

Medical Center ◽

Signs And Symptoms ◽

Adult Patients ◽

Ocular Surface Disease ◽

Tacrolimus Ointment ◽

Severity Scores

AimTo identify risk factors for the development of dupilumab-induced ocular surface disease (DIOSD) in adult patients with atopic dermatitis (AD) and describe outcomes of treatment.MethodsA retrospective institutional cohort study performed at the Rabin Medical Center, Petach Tikva, Israel. Adult patients with AD who received dupilumab from March 2018 to June 2019 were included. Demographics, AD severity scores, blood IgE levels, previous atopic keratoconjunctivitis (AKC), dermatological response to dupilumab, ophthalmological evaluation and treatment were noted. Univariate and multivariate analyses were used to identify risk factors for DIOSD.ResultsSixteen of 37 patients who were included in the study (43%) had new or exacerbated symptoms of ocular surface disease starting at 2 weeks following the first treatment. Three patients reported transient dry eye sensation which lasted 2 weeks; nine patients reported chronic dry eye sensation, and four patients (25%) had marked blepharoconjunctivitis. The presence of severe AD was the strongest predictor of DIOSD. Not a single patient with moderate AD had DIOSD. In multivariate analysis, prior AKC was a risk factor for DIOSD (R2=15.78, OR=23.28, p=0.005) while a family history of atopy was protective of DIOSD (R2=6.22, OR=0.13, p=0.05). All four patients with blepharoconjunctivitis had resolution of signs, and symptoms within days of starting periocular 0.03%–0.1% tacrolimus ointment.ConclusionsDIOSD is common in patients with AD receiving dupilumab. While most cases are mild, some patients can develop blepharoconjunctivitis which responds well to tacrolimus ointment. AD severity, and previous AKC are risk factors for DIOSD.

Download Full-text

INTENSE PULSED LIGHT (IPL) TREATMENT FOR DUPILUMAB INDUCED OCULAR SURFACE DISEASE (DIOSD)

Journal of Dry Eye Disease ◽

10.22374/jded.v5i1.40 ◽

2022 ◽

Vol 5 (1) ◽

pp. e1-e11

Author(s):

Sathi Maiti ◽

Laura M Periman ◽

Natasha Balani

Keyword(s):

Ocular Surface ◽

Anterior Segment ◽

Signs And Symptoms ◽

Intense Pulsed Light ◽

Ocular Surface Disease ◽

Topical Steroids ◽

Pulsed Light ◽

Traditional Treatment ◽

Adjunct Therapy ◽

Effective Adjunct

PurposeTo report a case of dupilumab induced ocular surface disease (DIOSD) managed with intense pulsed light (IPL) as an effective adjunct therapy to topical steroids and topical immunomodulator lifitegrast.MethodsDiscussion of a patient’s case with accompanying anterior segment and meibography photos with diagnosed DIOSD for which adjunct therapy with IPL was an effective treatment after limited relief from and difficulty with adherence to traditional treatment with topical steroids and lifitegrast ophthalmic solutions. ConclusionThis case demonstrates the complexity of management required to treat patients with DIOSD and its chronic nature. IPL as a nonpharmaceutical adjunct therapy to topical steroids and immunomodulators in the treatment of DIOSD showed improved signs and symptoms of DIOSD.

Download Full-text